Merck Animal Health Completes Acquisition of Vallée S.A.
March 22 2017 - 03:05PM
Business Wire
Broadening Our Comprehensive Portfolio of
Animal Health Products for Brazilian Market
Merck Animal Health (known as MSD Animal Health outside the
United States and Canada) today announced it has successfully
acquired a controlling interest in Vallée S.A., a leading
privately-held producer of animal health products in Brazil.
“The combined strength of the two companies under the umbrella
of MSD Animal Health will provide customers with a more
comprehensive portfolio of products for livestock animals,” said
Rick DeLuca, president, Merck Animal Health. “We will continue to
seek opportunities like these that complement our business and
bring value to our customers.”
About Merck Animal Health
For over a century, Merck Animal Health has been a global health
care leader working to help the world be well. Merck Animal Health,
known as MSD outside the United States and Canada, is the global
animal health business unit of Merck Animal Health. Through its
commitment to the Science of Healthier Animals™, Merck Animal
Health offers veterinarians, farmers, pet owners and governments
one of the widest range of veterinary pharmaceuticals, vaccines and
health management solutions and services. Merck Animal Health is
dedicated to preserving and improving the health, well-being and
performance of animals. It invests extensively in dynamic and
comprehensive R&D resources and a modern, global supply chain.
Merck Animal Health is present in more than 50 countries, while its
products are available in some 150 markets. For more information,
visit www.merck-animal-health.com or connect with us on
LinkedIn, Facebook and Twitter at @MerckAH.
Forward-Looking Statement of Merck & Co., Inc.,
Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J.,
USA (the “company”) includes “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These statements are
based upon the current beliefs and expectations of the company’s
management and are subject to significant risks and uncertainties.
If underlying assumptions prove inaccurate or risks or
uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of pharmaceutical industry regulation and health care
legislation in the United States and internationally; global trends
toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent
in new product development, including obtaining regulatory
approval; the company’s ability to accurately predict future market
conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk;
dependence on the effectiveness of the company’s patents and other
protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory
actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in the company’s 2016
Annual Report on Form 10-K and the company’s other filings with the
Securities and Exchange Commission (SEC) available at the SEC’s
Internet site (www.sec.gov).
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170322005156/en/
For MerckMedia:Noreen Verbrugge, 973-937-5450orPamela
Eisele, 267-305-3558orInvestors:Michael DeCarbo, 908-740-1807
Merck (NYSE:MRK)
Historical Stock Chart
From Feb 2024 to Mar 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2023 to Mar 2024